Literature DB >> 29439955

Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

Marina Wierz1, Sandrine Pierson1, Léa Guyonnet2,3, Elodie Viry1, Audrey Lequeux1, Anaïs Oudin4, Simone P Niclou4, Markus Ollert2,5, Guy Berchem1,6, Bassam Janji1, Coralie Guérin2,3, Jerome Paggetti1, Etienne Moussay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29439955      PMCID： PMC5887766          DOI： 10.1182/blood-2017-06-792267

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Differential effect of CD8(+) and CD8(-) dendritic cells in the stimulation of secondary CD4(+) T cells.

Authors:  V Kronin; C J Fitzmaurice; I Caminschi; K Shortman; D C Jackson; L E Brown
Journal:  Int Immunol       Date:  2001-04       Impact factor: 4.823

2.  PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Authors:  Takeru Asano; Yusuke Meguri; Takanori Yoshioka; Yuriko Kishi; Miki Iwamoto; Makoto Nakamura; Yasuhisa Sando; Hideo Yagita; John Koreth; Haesook T Kim; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Joseph H Antin; Robert J Soiffer; Yoshinobu Maeda; Mitsune Tanimoto; Jerome Ritz; Ken-Ichi Matsuoka
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

Review 3.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  TGF-β3-expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses.

Authors:  Tomohisa Okamura; Shuji Sumitomo; Kaoru Morita; Yukiko Iwasaki; Mariko Inoue; Shinichiro Nakachi; Toshihiko Komai; Hirofumi Shoda; Jun-Ichi Miyazaki; Keishi Fujio; Kazuhiko Yamamoto
Journal:  Nat Commun       Date:  2015-02-19       Impact factor: 14.919

6.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells.

Authors:  Sayuri Yamazaki; Diana Dudziak; Gordon F Heidkamp; Christopher Fiorese; Anthony J Bonito; Kayo Inaba; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

9.  Ligation of CD31/PECAM-1 modulates the function of lymphocytes, monocytes and neutrophils.

Authors:  C G Elias; J P Spellberg; B Karan-Tamir; C H Lin; Y J Wang; P J McKenna; W A Muller; M M Zukowski; D P Andrew
Journal:  Eur J Immunol       Date:  1998-06       Impact factor: 5.532

Review 10.  CD69: from activation marker to metabolic gatekeeper.

Authors:  Danay Cibrián; Francisco Sánchez-Madrid
Journal:  Eur J Immunol       Date:  2017-06       Impact factor: 5.532
View more
  46 in total

1.  PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Authors:  Bola S Hanna; Philipp M Roessner; Annika Scheffold; Billy M C Jebaraj; Yasmin Demerdash; Selcen Öztürk; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

Review 2.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

3.  T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.

Authors:  Fabienne Lucas; Michael Pennell; Ying Huang; Don M Benson; Yvonne A Efebera; Maria Chaudhry; Tiffany Hughes; Jennifer A Woyach; John C Byrd; Suohui Zhang; Desiree Jones; Xiangnan Guan; Christin E Burd; Ashley E Rosko
Journal:  Biol Blood Marrow Transplant       Date:  2019-08-21       Impact factor: 5.742

4.  Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy.

Authors:  Xiaojie Yu; Xiao Huang; Xiuxiu Chen; Jianfei Liu; Chenglin Wu; Qian Pu; Yuxiao Wang; Xiaoqiang Kang; Lijun Zhou
Journal:  MAbs       Date:  2019-06-26       Impact factor: 5.857

Review 5.  Lag3: From Bench to Bedside.

Authors:  Francesca Aroldi; Reem Saleh; Insiya Jafferji; Carmelia Barreto; Chantal Saberian; Mark R Middleton
Journal:  Cancer Treat Res       Date:  2022

Review 6.  Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.

Authors:  Fabien Thoreau; Vijay Chudasama
Journal:  RSC Chem Biol       Date:  2021-10-22

7.  Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues.

Authors:  Bola S Hanna; Philipp M Roessner; Haniyeh Yazdanparast; Dolors Colomer; Elias Campo; Sabrina Kugler; Deyan Yosifov; Stephan Stilgenbauer; Manfred Schmidt; Richard Gabriel; Peter Lichter; Martina Seiffert
Journal:  Leukemia       Date:  2018-09-28       Impact factor: 11.528

Review 8.  Development of Immunotherapy Combination Strategies in Cancer.

Authors:  Timothy A Yap; Eileen E Parkes; Weiyi Peng; Justin T Moyers; Michael A Curran; Hussein A Tawbi
Journal:  Cancer Discov       Date:  2021-04-02       Impact factor: 39.397

9.  Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling.

Authors:  Hannah Wurzer; Liza Filali; Céline Hoffmann; Max Krecke; Andrea Michela Biolato; Jérôme Mastio; Sigrid De Wilde; Jean Hugues François; Anne Largeot; Guy Berchem; Jérôme Paggetti; Etienne Moussay; Clément Thomas
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

10.  Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781.

Authors:  Joanne Ellis; Daniel J B Marks; Naren Srinivasan; Christine Barrett; Thomas G Hopkins; Anna Richards; Rainard Fuhr; Muna Albayaty; Martin Coenen; Lia Liefaard; Karen Leavens; Katherine L Nevin; Shuo Tang; Stephen A Hughes; Léa Fortunato; Ken Edwards; Yi Cui; Rabia Anselm; Christopher J Delves; Emilie Charles; Maria Feeney; Thomas M Webb; Sara J Brett; Tim S Schmidt; John Stone; Caroline O S Savage; Nicolas Wisniacki; Ruth M Tarzi
Journal:  Clin Pharmacol Ther       Date:  2020-11-24       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.